ストックスクリーナーアプリを入手
192.45
1.31%
-2.55
アフターアワーズ：
192.75
0.30
+0.16%
前日終値:
$195.00
開ける：
$193.89
24時間の取引高:
4.97M
Relative Volume:
0.68
時価総額：
$334.73B
収益：
$57.37B
当期純損益:
$4.20B
株価収益率:
81.89
EPS:
2.35
ネットキャッシュフロー:
$15.39B
1週間 パフォーマンス:
+1.67%
1か月 パフォーマンス:
+0.50%
6か月 パフォーマンス:
+9.86%
1年 パフォーマンス:
+13.27%
1日の値動き範囲:
$191.16
$194.00
1週間の範囲:
$186.67
$197.50
52週間の値動き範囲:
$163.81
$218.66
Abbvie Inc Stock (ABBV) Company Profile
ABBV を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
192.45 | 334.73B | 57.37B | 4.20B | 15.39B | 2.35 |
|
LLY
Lilly Eli Co
|
793.01 | 724.64B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
156.90 | 376.43B | 89.33B | 21.81B | 18.57B | 8.99 |
|
NVO
Novo Nordisk Adr
|
68.93 | 352.49B | 43.59B | 15.04B | 10.74B | 3.3766 |
|
NVS
Novartis Ag Adr
|
121.02 | 234.21B | 53.22B | 12.86B | 14.85B | 6.39 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-14 | ダウングレード | Citigroup | Buy → Neutral |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-12-05 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-04 | アップグレード | Argus | Hold → Buy |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-06-05 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-05-17 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-01-29 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | ダウングレード | HSBC Securities | Buy → Hold |
| 2023-12-11 | アップグレード | Goldman | Neutral → Buy |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-10-30 | アップグレード | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 再開されました | UBS | Neutral |
| 2023-09-29 | 開始されました | Raymond James | Outperform |
| 2023-07-25 | 開始されました | William Blair | Mkt Perform |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-04-05 | ダウングレード | Argus | Buy → Hold |
| 2023-03-01 | 開始されました | Guggenheim | Buy |
| 2023-02-22 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | アップグレード | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-11-08 | ダウングレード | Societe Generale | Buy → Hold |
| 2022-08-01 | ダウングレード | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Underperform |
| 2022-05-06 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | 再開されました | Morgan Stanley | Overweight |
| 2022-02-28 | ダウングレード | UBS | Buy → Neutral |
| 2022-02-03 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-03 | 繰り返されました | Barclays | Equal Weight |
| 2022-02-03 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-03 | 繰り返されました | Goldman | Neutral |
| 2022-01-13 | 開始されました | Redburn | Buy |
| 2022-01-12 | 繰り返されました | BMO Capital Markets | Outperform |
| 2021-12-09 | 再開されました | Wells Fargo | Overweight |
| 2021-11-23 | アップグレード | Societe Generale | Hold → Buy |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
| 2020-11-10 | 再開されました | Bernstein | Outperform |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-06-23 | アップグレード | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | アップグレード | Argus | Hold → Buy |
| 2020-05-18 | 再開されました | BofA/Merrill | Neutral |
| 2020-05-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-05-11 | 再開されました | Morgan Stanley | Overweight |
| 2020-04-20 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | ダウングレード | Societe Generale | Buy → Hold |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-02-06 | 開始されました | Mizuho | Buy |
| 2020-01-07 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | 繰り返されました | Cowen | Outperform |
| 2019-09-26 | アップグレード | Citigroup | Neutral → Buy |
| 2019-08-20 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | 開始されました | Goldman | Neutral |
| 2019-04-29 | アップグレード | BMO Capital Markets | Underperform → Market Perform |
すべてを表示
Abbvie Inc (ABBV) 最新ニュース
A New Playbook for Mid-Cap Biotechs: Glenmark's $700M Oncology Deal with AbbVie Signals Strategic Shifts - AInvest
The Smartest Dividend Stocks to Buy With $300 Right Now - The Motley Fool
A Drop of Innovation: AbbVie's Omega-3 Eye Drops and the Disruption of Dry Eye Care - AInvest
Refresh Releases First of its Kind Eye Drop for Dry Eyes - MarketScreener
AbbVie Announces Availability of Refresh Advanced OMEGA-3 Lubricant Eye Drops in Canada - MarketScreener
India's Glenmark Pharma soars 10% to record high on AbbVie cancer treatment licensing deal - Reuters
AbbVie and Genmab’s Promising Phase 3 Study for DLBCL: A Potential Game-Changer - The Globe and Mail
ABBV or BMY: Which Biopharma Giant Has Better Prospects for Now? - Yahoo Finance
AbbVie & IGI Enter Global Licensing Agreement for Trispecific Antibody - Contract Pharma
Dividend Roundup: CVS Health, Procter & Gamble, AbbVie, Colgate-Palmolive, and more (PG:NYSE) - Seeking Alpha
Boeing, Joby Aviation, Oracle And A Health Care Stock: CNBC's 'Final Trades' - Benzinga
Dividend Investors: Don't Be Too Quick To Buy AbbVie Inc. (NYSE:ABBV) For Its Upcoming Dividend - simplywall.st
AbbVie cuts $1.9bn+ deal with IGI for trispecific antibody - pharmaphorum
FiDi-based drug company inks $1B oncology deal with AbbVie - Crain's New York Business
Glenmark-AbbVie Deal Lifts Optimism on India’s Biotech Stocks - Bloomberg
Glenmark Pharma shares surge after its U.S arm, AbbVie ink pact for investigational cancer drug - The Hindu
India’s Glenmark Pharma shares hit record high on AbbVie cancer drug deal - Investing.com
Glenmark Unit to License Blood Cancer Drug to Abbvie for $700 Million Upfront - Bloomberg
Glenmark Pharma jumps on unit's cancer treatment licensing deal with AbbVie - MarketScreener
AbbVie Shares Climb on $700 Million Licensing Deal with IGI Therapeutics - MSN
AbbVie (ABBV) Laps the Stock Market: Here's Why - Yahoo Finance
Abbvie gains rights to IGI’s trispecific ISB-2001 in $1.9B+ deal - BioWorld MedTech
AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025 - insights.citeline.com
Wall Street Stunned: AbbVie Drops $700M on a Little-Known Indian Cancer Drug - Yahoo Finance
Why Is AbbVie Stock Trading Higher On Thursday? - Benzinga
AbbVie Strikes $2B Licensing Deal with IGI Therapeutics - USA Herald
AbbVie expands oncology pipeline with exclusive licensing agreement - The Business Journals
AbbVie Pays $700M for Drug Engineered to Overcome Resistance in Multiple Myeloma - MedCity News
Glenmark unit clinches $700mn licensing deal for its cancer drug | Company Business News - Mint
Pfizer and AbbVie Advance Pediatric Antibiotic Study with ATM-AVI - TipRanks
AbbVie Pays Up To $2B For Oncology Licensing Agreement - Law360
Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody - Yahoo Finance
AbbVie to pay $700M for trispecific drug from Ichnos Glenmark - BioPharma Dive
AbbVie stock jumps after $700 million licensing deal with IGI Therapeutics - Investing.com
Glenmark arm inks $700 million licensing deal with US-based AbbVie - Business Standard
AbbVie Scoops Up Ichnos Glenmark’s Lead Myeloma Antibody for Nearly $2B - BioSpace
India's Glenmark Pharma unit, AbbVie sign exclusive licensing pact - Reuters
AbbVie Enters Licensing Agreement For IGI Therapeutics’ Experimental Oncology Drug: Retail Cheers - Stocktwits
AbbVie and Ichnos Glenmark sign licensing deal for trispecific antibody - Seeking Alpha
AbbVie and Ichnos Glenmark ink antibody license deal - The Pharma Letter
AbbVie bets on 'new frontier' in immuno-oncology with $1.9B trispecific deal - FirstWord Pharma
AbbVie and Ichnos Glenmark Innovation Announce Exclusive Global Licensing Agreement for ISB 2001, a First-In-Class CD38xBCMAxCD3 Trispecific Antibody - MarketScreener
AbbVie Signs Deal With IGI Therapeutics To Develop ISB 2001 For Oncology, Autoimmune Diseases - Nasdaq
AbbVie licenses IGI’s multiple myeloma treatment in $1.9 billion deal - Investing.com
AbbVie Pays $700M Upfront for Revolutionary Triple-Target Cancer Drug in Billion-Dollar Deal - Stock Titan
Tax Court Breaks New Ground on the Deductibility of Termination Fees with AbbVie Ruling - proskauertaxtalks.com
Pharmaceutical giant AbbVie wants to expand its presence in Worcester - Worcester Telegram
Morgan Stanley Maintained an Overweight Rating on AbbVie (ABBV) - Insider Monkey
10 High Growth Dividend Paying Stocks to Buy - Insider Monkey
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Why AbbVie (ABBV) is a Top Value Stock for the Long-Term - Yahoo Finance
Abbvie Inc (ABBV) 財務データ
収益
当期純利益
現金流量
EPS
Abbvie Inc (ABBV) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Stewart Jeffrey Ryan | EVP, CHIEF COMMERCIAL OFFICER |
Mar 31 '25 |
Sale |
210.08 |
58,832 |
12,359,504 |
53,234 |
2.93%
大文字化:
|
ボリューム (24 時間):